Working… Menu

Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer (DEBATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04308174
Recruitment Status : Recruiting
First Posted : March 13, 2020
Last Update Posted : July 22, 2021
Samsung Medical Center
Information provided by (Responsible Party):
Changhoon Yoo, Asan Medical Center

Brief Summary:
Considering that the poor prognosis of resected biliary tract cancer and negative impact on the survival outcomes of R1/R2 resection, neoadjuvant chemotherapy may improve R0 resection rates and the survival outcomes of patients with resectable biliary tract cancer. The addition of durvalumab to gemcitabine/cisplatin as neoadjuvant chemotherapy may improve the R0 resection rates compared to gemcitabine/cisplatin in patients with localized biliary tract cancer. In this phase 2 trial, a total of 45 patients with localized biliary tract cancer will be 2:1 randomized to durvalumab plus gemcitabine/cisplatin or gemcitabine/cisplatin.

Condition or disease Intervention/treatment Phase
Biliary Tract Neoplasms Gallbladder Cancer Cholangiocarcinoma Drug: Durvalumab + Gem/Cis Drug: Gem/Cis Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin With or Without Durvalumab (MEDI4736) Followed by Postoperative Durvalumab (MEDI4736) in Patients With Localized Biliary Tract Cancer
Actual Study Start Date : May 20, 2020
Estimated Primary Completion Date : September 30, 2022
Estimated Study Completion Date : December 30, 2023

Arm Intervention/treatment
Experimental: Durvalumab + Gem/Cis

<Investigational arm: preoperative phase (up to 4 cycles)> Durvalumab 1,500 mg IV on Day 1, every 3 weeks (preop period) 1,500 mg IV Day 1, every 4 weeks (postop period) Gemcitabine 1,000 mg IV on Day 1 and 8, every 3 weeks Cisplatin 25 mg IV on Day 1 and 8, every 3 weeks

<Postoperative therapy for all patients (up to 6 cycles)> Durvalumab 1,500 mg IV Day 1, every 4 weeks (postop period)

Drug: Durvalumab + Gem/Cis
Neoadjuvant Durvalumab + Gemcitabine/Cisplatin

Active Comparator: Gem/Cis

<Control arm: preoperative phase (up to 4 cycles)> Gemcitabine 1,000 mg IV on Day 1 and 8, every 3 weeks Cisplatin 25 mg IV on Day 1 and 8, every 3 weeks

<Postoperative therapy for all patients (up to 6 cycles)> Durvalumab 1,500 mg IV Day 1, every 4 weeks (postop period)

Drug: Gem/Cis
Neoadjuvant Gemcitabine/Cisplatin

Primary Outcome Measures :
  1. Ro resection rate [ Time Frame: 4 months ]
    Surgical resection without any residual cancer

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 1 year ]
    Time between the start of study treatment and any cause of death

  2. Event-free survival [ Time Frame: 1 year ]
    Time between the start of study treatment and disease progression or any cause of death

  3. Adverse events [ Time Frame: 13 months ]
    Number of patients experiencing adverse events graded by National Cancer Institute Common Terminology Criteria version 5

  4. Response rate [ Time Frame: 4 months ]
    Graded by Response Evaluation Criteria in Solid Tumors version 1.1

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Age > 19 years at time of study entry
  • Histologically confirmed adenocarcinoma of biliary tract (intrahepatic, hilar or extrahepatic cholangiocarcinoma, or gallbladder carcinoma).
  • Localized, potentially resectable, non-metastatic disease (determined at the discretion of attending surgeons) based on the results of CT, MRI or PET-CT scans.
  • No active uncontrolled infection, except chronic viral hepatitis under antiviral therapy.
  • Eastern Cooperative Oncology Group (ECOG performance status of 0 or 1
  • Body weight >30kg
  • Adequate normal organ and marrow function
  • Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
  • No other malignant disease apart from non-melanotic skin cancer, carcinoma in situ of the uterine cervix, localized prostate or papillary thyroid cancer, or any other cancer where treated with curative intent > 5 years previously without evidence of relapse

Exclusion Criteria:

  • Medical or psychiatric conditions that compromise the patient's ability to give informed consent or to complete the protocol or a history of non-compliance
  • Obstruction of gastrointestinal tract
  • Active gastrointestinal bleeding
  • Myocardial infarction within 6 months prior to the study medication, and other clinically significant heart disease (e.g., unstable angina, congestive heart failure or uncontrolled hypertension)
  • Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardise compliance with the protocol
  • Combined hepatocellular carcinoma/cholangiocarcinoma is excluded.
  • History of allogenic organ transplantation.
  • History of another primary malignancy except for

    1. Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence
    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    3. Adequately treated carcinoma in situ without evidence of disease
  • Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart).
  • Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.
  • Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
  • Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04308174

Layout table for location contacts
Contact: Changhoon Yoo, MD, PhD +821099006798

Layout table for location information
Korea, Republic of
Asan Medical Center Recruiting
Seoul, Korea, Republic of, 05505
Contact: Changhoon Yoo, MD         
Principal Investigator: Changhoon Yoo, MD         
Sponsors and Collaborators
Asan Medical Center
Samsung Medical Center
Layout table for investigator information
Principal Investigator: Changhoon Yoo, MD, PhD Asan Medical Center
Layout table for additonal information
Responsible Party: Changhoon Yoo, Assistant professor, Asan Medical Center Identifier: NCT04308174    
Other Study ID Numbers: ESR-18-14059
First Posted: March 13, 2020    Key Record Dates
Last Update Posted: July 22, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: IPD sharing plan will be determined at the time of completion of the study.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Changhoon Yoo, Asan Medical Center:
Biliary tract cancer
Neoadjuvant chemotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Biliary Tract Neoplasms
Gallbladder Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Biliary Tract Diseases
Digestive System Diseases
Gallbladder Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents